No, the big run came on the back of MSB looking like they would have their gvhd treatment approved by the FDA. Then they were hit with the CRL and the market tossed out Cynata with MSB, despite the company pretty clearly distinguishing the superior manufacturing consistency of the Cymerus process.
What we need now is more data from clinical trials, which is exactly what we will receive over the next 12-36 months across a broad spectrum of indications. Assuming the data correlates with what has been given in the investor presentations, then a $100M market cap will be a distant memory.
Ann: Cynata Receives $1.39m R&D Tax Incentive Refund, page-7
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.020(6.06%) |
Mkt cap ! $55.68M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.0¢ | 30.0¢ | $3.969K | 13.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40000 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 2000 | 1 |
View Market Depth
| Last trade - 13.14pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
32.5¢ |
Change
-0.020 ( 4.84 %) |
||||
| Open | High | Low | Volume | ||
| 32.5¢ | 32.5¢ | 32.5¢ | 3814 | ||
| Last updated 10.02am 05/06/2024 ? | |||||
| CYP (ASX) Chart |